Cardiff Oncology Inc.

02/09/2026 | Press release | Distributed by Public on 02/09/2026 15:00

Initial Statement of Beneficial Ownership (Form 3)

FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
Lindsay Brigitte Ute
2. Date of Event Requiring Statement (Month/Day/Year)
01/27/2026
3. Issuer Name and Ticker or Trading Symbol
Cardiff Oncology, Inc. [CRDF]
(Last) (First) (Middle)
11055 FLINTKOTE AVENUE
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Accounting Officer
5. If Amendment, Date Original Filed (Month/Day/Year)
(Street)
SAN DIEGO, CA 92121
6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 27,431 D
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (1) 01/23/2028 Common Stock 1,753 $21.6 D
Stock Options (2) 06/20/2029 Common Stock 89,469 $2.48 D
Stock Options (3) 06/17/2030 Common Stock 96,192 $2.6 D
Stock Options (4) 06/10/2031 Common Stock 154,704 $7.98 D
Stock Options (5) 03/09/2032 Common Stock 131,568 $2.5 D
Stock Options (6) 03/15/2033 Common Stock 90,288 $1.72 D
Stock Options (7) 03/17/2034 Common Stock 95,040 $3.51 D
Stock Options (8) 03/11/2035 Common Stock 166,320 $3.58 D

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Lindsay Brigitte Ute
11055 FLINTKOTE AVENUE
SAN DIEGO, CA 92121
Chief Accounting Officer

Signatures

/s/ Brigitte Lindsay 02/09/2026
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) 1,198 vested on January 23, 2018. 185 vested on January 23, 2019, 2020 and 2021.
(2) 29,823 vested on June 20, 2020, 2021 and 2022.
(3) 32,064 vested on June 17, 2021, 2022 and 2023.
(4) 38,676 vested on June 10, 2022 and 3,223 vested monthly for 36 months thereafter.
(5) 32,892 vested on March 9, 2023 and 2,741 vest monthly for 36 months thereafter.
(6) 22,572 vested on March 15, 2024 and 1,881 vest monthly for 36 months thereafter.
(7) 23,760 vested on March 7, 2025 and 1,980 vest monthly for 36 months thereafter.
(8) 41,580 vest on March 11, 2026 and 3,465 vest monthly for 36 months thereafter.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
Cardiff Oncology Inc. published this content on February 09, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on February 09, 2026 at 21:00 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]